ExploreWatchlistsPricing
  1. JP-listed companies
  2. Oncolys BioPharma Inc.
  3. Financials
  4. Total current liabilities

Oncolys BioPharma Inc. (4588)

Market cap
¥73.3B
P/E ratio
Develops viral therapies for cancer treatment and severe infections, with lead candidate OBP-301 targeting solid tumors like esophageal cancer.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndTotal current liabilities (Million JPY)YoY (%)
Dec 31, 2025471+86.51%
Dec 31, 2024252-33.32%
Dec 31, 2023379+17.69%
Dec 31, 2022322-25.24%
Dec 31, 2021430+3.60%
Dec 31, 2020415-20.72%
Dec 31, 2019524+146.70%
Dec 31, 2018212-11.17%
Dec 31, 2017239+16.69%
Dec 31, 2016205+15.76%
Dec 31, 2015177-32.68%
Dec 31, 2014263

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat